Experienced in Primitive Neuroectodermal Tumor (PNET)

Antonio M. Pinto

Naples, IT 
Experienced in Primitive Neuroectodermal Tumor (PNET)
Naples, IT 
OverviewLocationsClinical Research

Overview

Antonio Pinto practices in Naples, Italy. Mr. Pinto is rated as an Experienced expert by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Mastoidectomy.

His clinical research consists of co-authoring 324 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Primitive Neuroectodermal Tumor (PNET).

Gender
Male

Locations

Naples, Italy
Other Locations
Milan, 20132, Italy
Sapienza, Italy
Palermo, 90127, Italy
Rome, Italy
Turin, Italy
Fisciano, Italy
Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study
Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Drug
Study Drugs: Romidepsin, CHOEP-21
Study Phase: Phase 1/Phase 2
A Randomized, Open-label, Multicenter, Phase III, 2-arm Study Comparing Efficacy and Tolerability of the Intensified Variant 'Dose-dense/Dose-intense ABVD' (ABVD DD-DI) With an Interim PET Response-adapted ABVD Program as Upfront Therapy in Advanced-stage Classical Hodgkin Lymphoma (HL).
A Randomized, Open-label, Multicenter, Phase III, 2-arm Study Comparing Efficacy and Tolerability of the Intensified Variant 'Dose-dense/Dose-intense ABVD' (ABVD DD-DI) With an Interim PET Response-adapted ABVD Program as Upfront Therapy in Advanced-stage Classical Hodgkin Lymphoma (HL).
Enrollment Status: Completed
Publish Date: August 08, 2025
Intervention Type: Drug
Study Drugs: Doxorubicin, Bleomycin, Vinblastine, Dacarbazine
Study Phase: Phase 3
Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Ibrutinib in Combination to Rituximab-CHOP Followed by Ibrutinib Maintenance in Untreated Patients With Activated-B-Cell (ABC)-DLBCL at Intermediate-high and High Risk (IPI ≥2)
Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Ibrutinib in Combination to Rituximab-CHOP Followed by Ibrutinib Maintenance in Untreated Patients With Activated-B-Cell (ABC)-DLBCL at Intermediate-high and High Risk (IPI ≥2)
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Drug
Study Drug: Ibrutinib
Study Phase: Phase 2
Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study by the Fondazione Italiana Linfomi.
Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study by the Fondazione Italiana Linfomi.
Enrollment Status: Completed
Publish Date: July 16, 2025
Idelalisib Plus Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma: a Phase 2, Single-arm, Multicentric Study
Idelalisib Plus Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma: a Phase 2, Single-arm, Multicentric Study
Enrollment Status: Terminated
Publish Date: November 21, 2024
Intervention Type: Drug
Study Drugs: Idelalisib, Obinutuzumab
Study Phase: Phase 2
A Phase 1 Trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
A Phase 1 Trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Enrollment Status: Completed
Publish Date: July 25, 2024
Intervention Type: Drug
Study Drug: Tinostamustine
Study Phase: Phase 1
A Phase II Study of Brentuximab Vedotin (BV) in the Treatment of Elderly Hodgkin Lymphoma (HL) Patients at First Relapse or With Primary Refractory Disease.
A Phase II Study of Brentuximab Vedotin (BV) in the Treatment of Elderly Hodgkin Lymphoma (HL) Patients at First Relapse or With Primary Refractory Disease.
Enrollment Status: Completed
Publish Date: December 22, 2020
Intervention Type: Drug
Study Phase: Phase 2
Is the Walking Football a Feasible Approach to Improve Health-related Quality of Life in Men With Prostate Cancer Receiving Androgen Deprivation Therapy? the PROSTATA_MOVE Randomized Controlled Trial.
Is the Walking Football a Feasible Approach to Improve Health-related Quality of Life in Men With Prostate Cancer Receiving Androgen Deprivation Therapy? the PROSTATA_MOVE Randomized Controlled Trial.
Enrollment Status: Unknown
Publish Date: January 13, 2020
Intervention Type: Behavioral
Study Phase: Not Applicable
View 7 Less Clinical Trials

323 Total Publications

Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.
Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 20, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Pinto's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 69 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile